The dosage is typically based on your premeal blood sugar level, the amount of carbohydrates in your meal, and how physically active you are
BPA and BPS exposure have been tied in numerous studies to metabolic dysfunction and obesity
However, the potential for side effects, particularly in vulnerable populations, necessitates careful monitoring and open communication between patients and healthcare providers
Not for injection or ingestion
GLP-1 receptor agonists, including Rybelsus, have been associated with an increased risk of gallbladder-related problems in patients who still have their gallbladder intact, such as cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation)
People with a BMI below 27 need further clinical evaluation to determine if a GLP-1 medication is appropriate for them